TABLE 1.
Characteristics of patients with biliary tract cancers (BTC) or controls (CTRL)
| Variable | Discovery set | n = 20 | p value | Validation set | n = 68 | p value |
|---|---|---|---|---|---|---|
| BTC | CTRL | BTC | CTRL | |||
| n = 11 | n = 9 | n = 34 | n = 34 | |||
| Age (years) | ||||||
| Median (range) | 77 (61–88) | 74 (66–84) | 0.676 | 75.5 (40–97) | 73.5 (40–90) | 0.792 |
| Sex | ||||||
| M:F | 7:4 | 5:4 | 0.535 | 25:9 | 25:9 | 1.000 |
| Disease | ||||||
| dCCA | 5 | N/A | N/A | 19 | N/A | N/A |
| GBC | 4 | N/A | N/A | 8 | N/A | N/A |
| pCCA | 2 | N/A | N/A | 7 | N/A | N/A |
| CBD stone | N/A | 9 | N/A | N/A | 32 | N/A |
| SOD | N/A | 0 | N/A | N/A | 2 | N/A |
| Comorbidity | ||||||
| HL | 3 (27.3%) | 4 (44.4%) | 0.423 | 10 (29.4%) | 11 (32.4%) | 0.793 |
| WBC, /μl | 6800 ± 2465 | 5288 ± 1584 | 0.068 | 6467 ± 2262 | 6485 ± 1640 | 0.536 |
| CRP, mg/dl | 2.08 ± 1.44 | 1.09 ± 1.00 | 0.087 | 1.70 ± 1.91 | 1.68 ± 1.80 | 0.995 |
| T‐bil, mg/dl | 5.82 ± 3.85 | 1.56 ± 0.83 | 0.002 | 6.88 ± 5.47 | 1.24 ± 0.73 | <0.001 |
| CEA, ng/ml | 4.44 ± 3.70 | 2.81 ± 1.77 | 0.323 | 5.83 ± 12.86 | 2.33 ± 1.05 | 0.051 |
| CA19‐9, U/ml | 1877.4 ± 5212.0 | 118.8 ± 262.8 | 0.087 | 410.7 ± 686.4 | 30.97 ± 34.24 | 0.002 |
| Stage | ||||||
| I | 1 | N/A | N/A– | 3 | N/A | N/A– |
| II | 5 | N/A | N/A | 18 | N/A | N/A |
| III | 2 | N/A– | N/A | 5 | N/A– | N/A– |
| IV | 3 | N/A– | N/A– | 8 | N/A– | N/A |
Abbreviations: CA19‐9, carbohydrate antigen 19‐9; CBD, common bile duct; CEA, carcinoembryonic antigen; CRP, C‐reactive protein; dCCA, distal cholangiocarcinoma; F, female; GBC, gallbladder cancer; HL, hyperlipidemia; M, male; N/A, not applicable; pCCA, perihilar cholangiocarcinoma; SOD, sphincter of Oddi dysfunction; T‐bil, total bilirubin; WBC, while blood cell.
The italic values, statistically significant.